MAPK Pathway – Medxy AI

Vosoritide Shows Promising Growth Benefits in Children with RASopathies and Related Genetic Short Stature Disorders

By MedXY 08/13/2026

A phase II basket trial demonstrates that vosoritide significantly increases growth velocity in children with RASopathies, ACAN, and NPR2 deficiencies, with an acceptable short-term safety profile, suggesting its potential as a precision therapy targeting MAPK pathway growth disorders.

Gastroenterology news Oncology

MAPK Pathway Mutations Drive Resistance to Ivosidenib in IDH1-Mutant Cholangiocarcinoma by Blunting Interferon Signaling

By MedXY 01/11/2026

A comprehensive longitudinal ctDNA analysis of patients from the ClarIDHy phase III trial reveals that MAPK pathway alterations, including KRAS and NRAS mutations, are primary drivers of acquired resistance to ivosidenib by suppressing critical interferon-gamma-mediated antitumor responses.